Kezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)

Cash, cash equivalents and marketable securities totaled $100.8 million as of June 30, 2025, compared to $132.2 million as of December 31, 2024. The decrease was primarily attributable to cash used in operations. “We are on track with our clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis,” said Chris Kirk, PhD, CEO and co-founder of Kezar. “We are committed to working closely with the FDA to align on our next trial design, which we have proposed as a registration-enabling study. The Type C meeting will be an important milestone as we continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with autoimmune hepatitis.”